Ultime notizie per Lexeo Therapeutics (NASDAQ:LXEO) Azioni

LEXEO THERAPEUTICS INC

Lexeo Therapeutics

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

Lexeo Therapeutics Inc

Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) reported quarterly losses of $(0.14) per share. This is a 99.47 percent increase over losses of $(26.23) per share from the same period last year. The company reported $316.00 thousand in sales this quarter. This is a 15.70K percent increase over sales of $2.00 thousand the same period last year.

Earnings

News

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

Reported May 8, 2025: Faraday Future Q1 EPS $(0.14) Up From $(26.23) YoY, Sales $316.00K Up From $2.00K YoY

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) has outperformed the market over the past 10 years by 5.35% on an annualized basis producing an average annual return of 15.62%. Currently, Guidewire Software has a market capitalization of $17.91 billion. 
Buying $100 In GWRE: If an investor had bought $100 of GWRE stock 10 years ago, it would be worth $411.90 today based on a price of $213.57 for GWRE at the time of writing.
<h3>Guidewire Software's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746832511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

GWRE

$100 Invested In Guidewire Software 10 Years Ago Would Be Worth This Much Today

At 61, many people are daydreaming about what their retirement will look like — morning coffee in the garden, long vacations, or maybe learning how to pickle things just because they can.
Ruth and her husband? They're just hoping retirement is even an option.
"We're wondering if it's too late for us," Ruth told <a href="https://youtu.be/Cnf_QBYvVOc?si=76fDVZPMDJBUpk2q">Dave Ramsey on an episode of The Ramsey Show</a>. She's 61, her husband's 60. And despite earning $130,000 a year, they've only managed to save $75,000 in their 401(k).
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
That's not the only number working against them. They owe $137,000 on their house, another $10,000 on a car loan, and a couple thousand more on credit cards and bills.
Ramsey didn't waste time cutting to the chase. "He makes way too much money for you all to be this broke," he said. Ruth's husband has already accepted his backup plan: work until he drops. Not exactly the dream.
And Ramsey had a pretty bleak — and honestly gross — take on where they were headed. "If you keep spending like you've been spending and stay disorganized like you have been, you're going to retire on dog food," he warned.
That wasn't just a figure of speech. Without major changes, Ruth and her husband could be trading retirement for working forever — or living on whatever's cheapest at the grocery store.
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
But it's not hopeless. Ramsey laid out a brutal but doable plan: stop spending, kill the car and credit card debt, build a $15,000 emergency fund, invest 15% of their income, and throw everything else at the mortgage.
"You guys are going to have to get very, very serious today," Ramsey said.
No more vacations. No more eating out — "unless you're working there," Ramsey joked.
It's worth mentioning this call took place back in 2014, when retirement savings benchmarks were much lower. At that time, <a href="https://www.fidelity.com/bin-public/060_www_fidelity_com/documents/18608-02-ExecSum.pdf">Fidelity reported</a> the average 401(k) balance was $91,300. So despite Ramsey's critical take, Ruth and her husband weren't quite the financial disaster he made them out to be. By 2014 standards — and considering wage levels back then — they were actually pretty much on par.
Of course, by today's standards, they'd be trailing badly. <a href="https://newsroom.fidelity.com/pressreleases/fidelity--q4-2024-retirement-analysis--retirement-savers-achieve-positive-momentum-through-2024/s/bbd405d1-c640-4be9-9c7b-67a8fd38e2bb">Fidelity's 2025 report</a> shows the average balance for 60-64 year olds is $246,500.&nbsp;
If they stuck to the plan, Ramsey believed they could retire in seven to nine years with about $500,000 saved and no house payment.
That's a <a href="https://www.benzinga.com/money/smartasset">future worth fighting for</a>. Because the alternative? Dog food.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Donald Trump just announced a $500 billion AI infrastructure deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">here's how you can invest in the entertainment market's next big disruptor at $2.25 per share</a>.</li>
</ul>
Image: Shutterstock

Personal Finance

'Too Late To Retire?' 61-Year-Old Couple Has $75K In 401(k) Despite $130K Salary — Dave Ramsey Warns They'll 'Retire On Dog Food' At This Rate

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and lowers the price target from $54 to $45.

Price Target

Analyst Ratings

RCKT

Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $45

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Buy and lowers the price target from $28 to $25.

FDMT

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

UBS analyst Trung Huynh maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and lowers the price target from $44 to $38.

CLDX

UBS Maintains Buy on Celldex Therapeutics, Lowers Price Target to $38

Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) has outperformed the market over the past 20 years by 8.79% on an annualized basis producing an average annual return of 16.95%. Currently, Domino's Pizza has a market capitalization of $16.40 billion. 
Buying $1000 In DPZ: If an investor had bought $1000 of DPZ stock 20 years ago, it would be worth $22,913.88 today based on a price of $478.90 for DPZ at the time of writing.
<h3>Domino's Pizza's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746829811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Domino's Pizza 20 Years Ago Would Be Worth Today

UBS analyst Christopher Schoell maintains Cogent Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NASDAQ">CCOI</a>) with a Buy and lowers the price target from $102 to $75.

CCOI

UBS Maintains Buy on Cogent Comms Hldgs, Lowers Price Target to $75

UBS analyst Josh Silverstein maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Buy and lowers the price target from $32 to $30.

CTRA

UBS Maintains Buy on Coterra Energy, Lowers Price Target to $30

UBS analyst Steven Fisher maintains Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) with a Buy and lowers the price target from $154 to $152.

UBS Maintains Buy on Jacobs Solutions, Lowers Price Target to $152

UBS analyst Trung Huynh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and lowers the price target from $110 to $109.

INSM

UBS Maintains Buy on Insmed, Lowers Price Target to $109

UBS analyst Peter Grom maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Neutral and lowers the price target from $63 to $59.

UBS Maintains Neutral on Molson Coors Beverage, Lowers Price Target to $59

UBS analyst Dan Leonard maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Buy and lowers the price target from $95 to $70.

TECH

UBS Maintains Buy on Bio-Techne, Lowers Price Target to $70

UBS analyst John Lovallo maintains Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) with a Neutral and lowers the price target from $74 to $72.

TREX

UBS Maintains Neutral on Trex Co, Lowers Price Target to $72

UBS analyst Kevin Caliendo maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and lowers the price target from $27 to $25.

XRAY

UBS Maintains Buy on Dentsply Sirona, Lowers Price Target to $25

UBS analyst Kunal Madhukar maintains ZipRecruiter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIP#NYSE">ZIP</a>) with a Neutral and lowers the price target from $7 to $6.

UBS Maintains Neutral on ZipRecruiter, Lowers Price Target to $6

UBS analyst Seth Gilbert maintains Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) with a Neutral and lowers the price target from $3.5 to $2.

VERI

UBS Maintains Neutral on Veritone, Lowers Price Target to $2

UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) with a Neutral and lowers the price target from $10 to $8.6.

TMCI

UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $8.6

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 10 years by 2.1% on an annualized basis producing an average annual return of 12.37%. Currently, UnitedHealth Group has a market capitalization of $344.73 billion. 
Buying $1000 In UNH: If an investor had bought $1000 of UNH stock 10 years ago, it would be worth $3,285.34 today based on a price of $380.02 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746828911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 10 Years

UBS analyst Kevin Mcveigh maintains Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) with a Neutral and lowers the price target from $2.95 to $1.9.

UBS Maintains Neutral on Rackspace Technology, Lowers Price Target to $1.9

Press Releases

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Management

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Comments

Lexeo Therapeutics

Notizie

Ultime notizie per Lexeo Therapeutics (NASDAQ:LXEO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO